next

Next

This will not be the first time animal leather has been disrupted – the 20th century saw the rise of artificial leathers synthesized from petrochemicals at a third of the cost. They now represent about two thirds of the overall leather market. But this alternative also generates environmental impacts related to contamination by plastics, CO2 footprint, and the release of toxic chemicals to the environment. Hence, there is an urgent need to develop NEXT and new alternatives to both animal and synthetic leather.

Gen

The objective is to develop cultured leather which require less time of manufacturing, without land or chemicals, and much lower water and energy inputs. At high scale, cultured leather can provide a safe, sustainable and economical alternative to the traditional tanning and chemical industry and it will help to mitigate the climate emergency.

From a technical perspective, our approach integrates innovations in cell culture and biofabrication to get a leather with the best properties of durability, strenght and elasticity, offering GENetic solutions to coming GENerations.

leather
gen

Leather

Beef cattle are raised for an average of 18 months before being slaughtered, at which point the process of turning hides into leather begins. The full tanning, dyeing, and finishing process takes between six to eight weeks. After the hide is processed, it may be shipped to finished goods companies to be cut and sewn into products. Next-Gen Leather addressed this challenge by developing an eco-friendly leather-like material that requires less time, water and energy to manufacture and employs no harmful chemicals: BacLEATHER®.

«As recognition of this innovative approach BacLEATHER® project has been granted under the EU SME Instrument programm Phase 1. Furthermore, we have also received two EU Seals of Excellence that means a quality label that consolidates our project as a highly innovative company at international level».

C. García, PHD & MBA

Co-Founder & CEO

After a degree in Biology (Extraordinary Degree Award) and a PhD in Biochemistry and Molecular Biology in virus research from the Universidad de Santiago de Compostela, she made a MBA at IE Business School, Madrid.

She worked for 14 years for Bio-Rad Laboratories, an international biotech company as Account Manager at Life Science Group for research market.

Later, for Food Science Division as Business Development Manager in charge of Transmissible Spongiform Encephalitis detection kits (mad cow disease) and was involved in biotech automation processes. She was also Key Account Manager for
industrial markets / microbiology testing and molecular diagnostics (PCR).

Co-Founder and CEO of Patent Shoes, S.L. and Founder of Patent Shoes Biotech, S.L. she is also owner of the luxury shoes brand Un pie en Versailles®. On the
BacLEATHER® Project she could combine her two passions: Science for Design.

Previously developed by Patent Shoes, BacLEATHER® project has received funding on 2021 from BeAble Capital to create the new company Next-Gen Leather. Both the investment as the participation of BeAble investors´ board in the project will allow production is scale up and deploy BacLEATHER® into consumer goods.

Board of investors

BeAble Capital SGEIC SA, Venture of reference in Science Equity (Technology Transfer funds focused on Deep Science), through its fund BeAble Innvierte Kets Fund, FCR, invest in Seed and Early Stage in the Industrial High Technology sector with the goal of transferring to society the technologies born in academic and research institutions in Spain and providing support for transforming breakthrough discoveries into products through start-ups.

Almudena Trigo

David López

Roberto Ranera

Alberto Díaz

Team

Elvira Marín, PHD

CTO

Graduated in Chemistry, she received her PhD in Biochemistry and Molecular Biology from the Autonomous University of Madrid and has more than 17 years of experience in Research, focused on Microbial Biotechnology.

Elvira has extensive experience in surface proteins and secretion systems of bacteria, focused on the identification of new candidates to treat bacterial infections as well as for diagnostic applications. In addition, she has a great knowledge in microscopy techniques and tissue sample preparation.

After several years working at Academy, Elvira was looking forward to finding new
opportunities within the biotech industry. As a scientist, she has developed great analytical skills and a great capacity for both problem solving and decision making. She works very well within a innovative team environment enjoying challenges and developing new skills.

V. de Lorenzo, PHD

Co-Founder & Intl. Strategy Consultant

CSIC Professor and Program Director at the Centro Nacional de Biotecnología (CSIC) in Madrid. After receiving his PhD in Biochemistry from the Universidad Autónoma de Madrid, he worked at the Pasteur Institute and the University of California, Berkeley

He is the author of more than 400 peer-reviewed articles, member of the European Molecular Biology Organization (EMBO) and a Fellow of the American Academy of Microbiology (AAM) and the European Academy of Microbiology (EAM). He has chaired the European Group of Life Sciences and was advisor to the Research Commissioner of the EC.

He has received various national and international awards for his contribution to Molecular Microbiology, Environmental Biotechnology and Microbial Ecology. He is also co-author in many patents as well as co founder at Microbionta, S.L. and BacMine, S.L. being in charge of contacts with investors and strategic alliances.

L.A. Fernández, PHD

Co-Founder & Scientist Consultant

CSIC Senior Scientist at the Centro Nacional de Biotecnología (CSIC) in Madrid. He received his PhD from the Universidad Autónoma de Madrid and was a visiting port-doctoral scientist at the University of California in San Francisco.

His experimental work has focused on the development of novel E.coli expression systems to obtain single domain antibodies in either the cytoplasm, the periplasm or the bacterial surface.

Luis Ángel´s work has pioneered the genetic engineering of bacteria to express and direct antibody-like proteins useful for biotechnological applications. He is co  author in many patents and co-founder at Microbionta, S.L. , BacMine, S.L. and Patent Shoes, S.L. He has hold contracts with several American companies to develop ad-hoc processes.

Contact Info

NEXT-GEN LEATHER, S.L.

Qube Technology Park
C/ Santiago Grisolía, 2
28760 – Tres Cantos – Madrid

info@next-genleather.com

Get in touch

Please contact us, our support team will answer all your questions.